– USA, PA – Optinose (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced the additions of Dr. Eric Bednarski (Ph.D.) and Dr. Kyle Dempsey (MD) to its Board of Directors.
“We are pleased to welcome Eric and Kyle to the Optinose Board of Directors. Their experience of successfully leading and overseeing investments in the global healthcare sector make them valuable additions to our Board of Directors,” said Board chairman, Joe Scodari.
Both currently serve as Partners at MVM Partners LLP, a growth equity firm that has invested in innovative, high growth healthcare businesses since 1997. With teams in Boston and London, MVM has a successful track record of investing across most healthcare sub-sectors, including: medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, and digital health.
About Dr. Eric Bednarski
Before joining MVM in 2008, Eric was a Partner at Advent Healthcare Ventures and a Principal at Advent International Corporation. Prior to Advent, he was a Director in the Corporate Finance Group of Silicon Valley Bank. E
ric has a B.S. in Neural Science from Brown University and a Ph.D. in Biological Sciences from the University of California, Irvine.
About Dr. Kyle Dempsey
Before joining MVM in 2017, Kyle was a consultant at Bain & Company, working mainly in the healthcare practice to support medical device and healthcare provider clients with commercialization and business development projects.
He received his M.D. from Harvard Medical School and his M.B.A. from Harvard Business School. He also holds an B.A. in biochemistry from Bowdoin College.
About Optinose
Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat and allergy specialists. Optinose has offices in the U.S. and Norway.
For more information : https://www.optinose.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
